...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: TNBC no longer active?
Reply New Message
Prev Message Back To Forum Threaded View Next Message

I'm not sure that's true for the two phase 2's. Zenith is still listed as the sponsor on both so has control.

In order to run these trials, Zenith sold a licence to Newsoara for ZEN-3694 in Asia. Part of the deal was that Newsoara would fund development costs.

News article here.

 

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply